Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

Company Overview

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $7.12 to $7.58
• 50-Day Range: $6.76 to $11.14
• 52-Week Range: $56.35 to $105.00
• Volume: 77,779 shs
• Average Volume: 12,438 shs
• Market Capitalization: $217.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AVTE Stock Analysis - Frequently Asked Questions

How have AVTE shares performed this year?

Aerovate Therapeutics' stock was trading at $92.75 on January 1st, 2025. Since then, AVTE stock has decreased by 91.9% and is now trading at $7.49.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its earnings results on Friday, April, 25th. The company reported ($3.15) earnings per share for the quarter, topping the consensus estimate of ($10.50) by $7.35.

When did Aerovate Therapeutics' stock split?

Shares of Aerovate Therapeutics reverse split before market open on Tuesday, April 29th 2025.A 1-35 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Aerovate Therapeutics IPO?

Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aerovate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 4/25/2025
• Today: 8/09/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVTE
• CIK: 1798749
• Web: aerovatetx.com
• Phone: 617-443-2400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -90.19%
• Return on Assets: -77.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.78
• Quick Ratio: 8.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.96 per share
• Price / Book: 1.89

Miscellaneous

• Outstanding Shares: 28,985,000
• Free Float: 21,685,000
• Market Cap: $217.10 million
• Optionable: Optionable
• Beta: 0.95